Biopharmaceutical Contract Manufacturing Market Demand, Size and Competitive Analysis | TechSci Research

Global Biopharmaceutical Contract Manufacturing Market was valued at USD 38.25 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 11.01% through 2029. <table><tr><td>Pages</td><td>180</td></tr> <tr><td>Market Size</td><td>2023: USD 38.25 Billion</td></tr> <tr><td>Forecast Market Size</td><td>2029: USD 71.74 Billion</td></tr> <tr><td>CAGR</td><td>2024-2029: 11.01%</td></tr> <tr><td>Fastest Growing Segment</td><td>Mammalian Source</td></tr> <tr><td>Largest Market</td><td>North America</td></tr> <tr><td>Key Players</td><td>1.Boehringer Ingelheim International GmbH2.Lonza Group Ltd3.Rentschler Biopharma SE 4.JRS PHARMA GmbH & Co. KG5.AGC Biologics6.ProBioGen AG7.FUJIFILM Diosynth Biotechnologies8.TOYOBO CO., LTD.9.Samsung Biologics10.Thermo Fisher Scientific Inc</td></tr> </table>

全球生物制药合同制造市场规模于2023年达到382.5亿美元，预计在预测期内将实现令人瞩目的增长，复合年增长率(CAGR)将达到11.01%，预计到2029年将达到717.4亿美元。

<table>
<tr>
<td>页数</td><td>180</td>
</tr>
<tr>
<td>市场规模</td><td>2023年：382.5亿美元</td>
</tr>
<tr>
<td>预测市场规模</td><td>2029年：717.4亿美元</td>
</tr>
<tr>
<td>CAGR</td><td>2024-2029年：11.01%</td>
</tr>
<tr>
<td>增长最快的细分市场</td><td>哺乳动物来源</td>
</tr>
<tr>
<td>最大市场</td><td>北美</td>
</tr>
<tr>
<td>主要参与者</td><td>1.Boehringer Ingelheim International GmbH2.Lonza Group Ltd3.Rentschler Biopharma SE 4.JRS PHARMA GmbH & Co. KG5.AGC Biologics6.ProBioGen AG7.FUJIFILM Diosynth Biotechnologies8.TOYOBO CO., LTD.9.Samsung Biologics10.Thermo Fisher Scientific Inc</td>
</tr>
</table>